DiaSorin (OTCMKTS:DSRLF) Shares Gap Up – What’s Next?

DiaSorin S.p.A. (OTCMKTS:DSRLF)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $74.25, but opened at $81.00. DiaSorin shares last traded at $81.00, with a volume of 100 shares traded.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on DSRLF. UBS Group cut DiaSorin from a “buy” rating to a “neutral” rating in a research report on Thursday, April 9th. Deutsche Bank Aktiengesellschaft cut DiaSorin from a “hold” rating to a “sell” rating in a report on Wednesday, June 17th. Piper Sandler began coverage on DiaSorin in a research note on Thursday, June 11th. They issued a “neutral” rating for the company. Finally, Zacks Research raised DiaSorin to a “hold” rating in a report on Tuesday, May 12th. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold”.

DiaSorin Stock Performance

The stock’s fifty day moving average is $73.97 and its two-hundred day moving average is $75.99.

About DiaSorin

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.